Inside the eye
The pressure inside the eye.
Medical Device · Glaucoma
Glaucoma is a two-pressure disease.
QMAX is the first implant built to treat it that way.
We built QMAX to equalize pressure across the optic nerve head, addressing the underlying mechanism behind vision loss in glaucoma
Glaucoma is the world's leading cause of irreversible blindness.
Worldwide, tens of millions live with glaucoma. Today's surgeries and drugs lower intraocular pressure (IOP), and yet vision loss continues. The reason is mechanical, and it has been hiding in plain sight.
~85M
people living with glaucoma globally
1 in 4
patients will go blind in at least one eye from glaucoma
The optic nerve is exposed to two different pressures.
Around the optic nerve
The pressure in the fluid space around the optic nerve.
The pressure difference between the inside of the eye and the fluid space around the optic nerve is called the translaminar gradient. This pressure strains the nerve and kills vision.
Treating IOP alone leaves half the equation untouched.
Over the past decade, the field has increasingly converged on this gradient as a primary driver of vision loss, and QMAX is built to address it directly.
QMAX equalizes the pressure gradient.
QMAX is a first-in-class implant that links the fluid inside the eye with the fluid space around the optic nerve. By balancing the two pressures, QMAX is designed to relieve strain on the optic nerve head, without a filtering bleb and without anti-fibrotics.
Mechanism-led.
Built to address normal-tension glaucoma, not just high IOP.
No bleb.
A closed pathway, with no bleb to manage or revise.
No anti-fibrotics.
No reliance on mitomycin C or anti-scarring agents.
Endoscopic delivery.
QSCOPE, a single-use endoscopic system designed for the high turnover workflow.
Built by surgeons, engineers, and operators.
LIQID is led by a glaucoma surgeon-founder and a multidisciplinary team across biomedical engineering, clinical research, regulatory, and quality, headquartered in Minneapolis.
Two-pressure model
TLPG · live read
IOP↑
Inside the eye
ICP↓
Around the optic nerve
QMAX equalizes the gradient
Backed by the names that shaped modern glaucoma surgery.
Our advisors and KOLs include leaders in glaucoma, robotics, and ophthalmic device commercialization. Named advisors and KOL quotes published only when cleared. See Company.
Supported by
Three ways to move QMAX forward.
Investors
We are advancing QMAX through Bridge financing toward Series A and US clinical milestones. If preventing blindness from glaucoma is your thesis, we want to talk.
Open an investor conversationStrategic partners
Surgical innovators, distributors, and strategics: QMAX is built for the high turnover workflow and the next paradigm of glaucoma care.
Discuss partnershipTalent
We hire engineers, clinical researchers, and regulatory professionals who want their work to matter.
Email careers@liqidmedical.com